- The independent Data & Safety Monitoring Board for the Phase IIb trial of Aastrom Biosciences' (ASTM) ixmyelocel-T for the treatment of advanced heart failure has recommended that the study continue without any changes.
- The recommendation follows an interim review of safety data.
- Aastrom expects to complete enrollment for the trial in H2.
- Shares are +6.5%. (PR)
Aastrom gets go-ahead to continue Phase IIb trial of heart drug
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs